CSIMarket
 


Moderna Inc   (MRNA)
Other Ticker:  
 

Moderna Inc 's Quick Ratio

MRNA's quarterly Quick Ratio and Cash & cash equivalent, Current Liabilities growth




MRNA Quick Ratio (Sep 30 2022)
III. Quarter
(Jun 30 2022)
II. Quarter
(Mar 31 2022)
I. Quarter
(Dec 31 2021)
IV. Quarter
(Sep 30 2021)
III. Quarter
Y / Y Current Liabilities Change -31.64 % -22.94 % 9.36 % 107.98 % 575.71 %
Y / Y Cash & cash equivalent Change -6.27 % -1.16 % 30.77 % 132.81 % 171.83 %
Quick Ratio MRQ 1.23 1.16 1.09 1.18 0.89
Overall Ranking # 1831 # 0 # 0 # 685 # 2592
Seq. Current Liabilities Change -0.07 % -26.26 % 1.21 % -8.33 % 12.64 %
Seq. Cash & cash equivalent Change 5.71 % -21.93 % -5.71 % 20.45 % 11.46 %



Quick Ratio third quarter 2022 Comment
Moderna Inc 's Cash & cash equivalent grew by 5.71 % in the III. Quarter sequntially, while Current Liabilities decreased, this led to improvement in Moderna Inc 's Quick Ratio to 1.23, Quick Ratio remained below Moderna Inc average.

Within Biotechnology & Pharmaceuticals industry 191 other companies have achieved higher Quick Ratio than Moderna Inc in third quarter 2022. While Quick Ratio total ranking has deteriorated compare to the prior quarter from 0 to 1831.

Explain Quick Ratio?
What are MRNA Segments?
See Quick Ratio MRNA on the trailing twelve month basis
Quick Ratio third quarter 2022 Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry # 192
Healthcare Sector # 737
Overall Market # 1831


Quick Ratio Statistics
High Average Low
16.81 1.28 0
(Jun 30 2020)   (Sep 30 2017)




Financial Statements
Moderna Inc 's Current Liabilities $ 6,807 Millions Visit MRNA's Balance sheet
Moderna Inc 's Cash & cash equivalent $ 8,348 Millions Visit MRNA's Balance sheet
Source of MRNA's Sales Visit MRNA's Sales by Geography


Cumulative Moderna Inc 's Quick Ratio

MRNA's Quick Ratio for the trailling 12 Months

MRNA Quick Ratio

(Sep 30 2022)
III. Quarter
(Jun 30 2022)
II. Quarter
(Mar 31 2022)
I. Quarter
(Dec 31 2021)
IV. Quarter
(Sep 30 2021)
III. Quarter
Y / Y Current Liabilities TTM Growth -31.64 % -22.94 % 9.36 % 107.98 % 575.71 %
Y / Y Cash & cash equivalent TTM Growth -6.27 % -1.16 % 30.77 % 132.81 % 171.83 %
Quick Ratio TTM 1.16 1.07 1.02 0.97 0.92
Total Ranking TTM # 1548 # 2110 # 2142 # 1648 # 1958
Seq. Current Liabilities TTM Growth -0.07 % -26.26 % 1.21 % -8.33 % 12.64 %
Seq. Cash & cash equivalent TTM Growth 5.71 % -21.93 % -5.71 % 20.45 % 11.46 %


TTM Quick Ratio Comment
On the trailing twelve months basis Current Liabilities decreased faster than Moderna Inc 's average Cash & cash equivalent, this led to increase in in Moderna Inc 's Quick Ratio to 1.16, Quick Ratio remained below MRNA average.
Quick Ratio is the average cumulative value over the last four quarters.

Among companies operatig within Biotechnology & Pharmaceuticals industry 196 other companies have achieved higher Quick Ratio than Moderna Inc . While overall ranking remained unchanged compare to previous quarter at no. 1548.

Explain Quick Ratio?
What are MRNA Segments?
See Quick Ratio MRNA on the trailing twelve month basis

TTM Quick Ratio Company Ranking
Within: No.
Within the Biotechnology & Pharmaceuticals Industry # 197
Healthcare Sector # 742
Within the Market # 1548


TTM Quick Ratio Statistics
High Average Low
12.46 2.04 0.05
(Jun 30 2020)   (June 30. 2013)




Companies with similar Quick Ratio in the quarter ending Sep 30 2022, within Biotechnology & Pharmaceuticals Industry Quick RatioSep 30 2022 MRQ Cash & cash equivalentSep 30 2022 MRQ Current Liabilities
Skyx Platforms Corp   3.29 $ 18.161  Millions$ 5.516  Millions
Immucell Corp  3.25 $ 8.828  Millions$ 2.715  Millions
Inogen Inc   3.19 $ 209.633  Millions$ 65.736  Millions
Regenxbio Inc   3.10 $ 382.418  Millions$ 123.548  Millions
Denali Therapeutics Inc   3.07 $ 1,106.055  Millions$ 360.670  Millions
Greenlight Biosciences Holdings Pbc  3.03 $ 98.353  Millions$ 32.416  Millions
Adaptimmune Therapeutics Plc  3.02 $ 199.670  Millions$ 66.080  Millions
Vaxart Inc   2.94 $ 63.999  Millions$ 21.740  Millions
Lineage Cell Therapeutics Inc   2.92 $ 66.355  Millions$ 22.739  Millions
Orchard Therapeutics Plc  2.92 $ 146.554  Millions$ 50.265  Millions
X4 Pharmaceuticals Inc  2.90 $ 79.855  Millions$ 27.549  Millions
Aspira Women s Health Inc   2.84 $ 20.551  Millions$ 7.224  Millions
Lakeland Industries Inc   2.74 $ 34.949  Millions$ 12.741  Millions
Gamida Cell Ltd   2.70 $ 61.295  Millions$ 22.713  Millions
Milestone Scientific Inc   2.67 $ 9.812  Millions$ 3.676  Millions
Achieve Life Sciences Inc   2.63 $ 18.197  Millions$ 6.916  Millions
Akoya Biosciences Inc   2.58 $ 81.704  Millions$ 31.682  Millions
Sangamo Therapeutics Inc   2.56 $ 313.568  Millions$ 122.361  Millions
Lifeloc Technologies Inc   2.55 $ 2.125  Millions$ 0.832  Millions
Oncocyte Corporation  2.47 $ 32.053  Millions$ 12.952  Millions
Seagen Inc   2.43 $ 1,763.702  Millions$ 725.998  Millions
Halozyme Therapeutics Inc   2.43 $ 265.584  Millions$ 109.384  Millions
Windtree Therapeutics Inc  2.39 $ 8.436  Millions$ 3.535  Millions
Oyster Point Pharma Inc   2.36 $ 68.800  Millions$ 29.197  Millions
Nanostring Technologies Inc   2.30 $ 117.069  Millions$ 50.939  Millions
Logicbio Therapeutics Inc   2.04 $ 30.780  Millions$ 15.098  Millions
Establishment Labs Holdings Inc   2.02 $ 65.349  Millions$ 32.376  Millions
Ayala Pharmaceuticals Inc   1.96 $ 11.195  Millions$ 5.705  Millions
Telesis Bio Inc   1.93 $ 24.741  Millions$ 12.808  Millions
Edwards Lifesciences Corporation  1.89 $ 1,738.700  Millions$ 917.900  Millions

Date modified: 2022-11-05T23:20:07+00:00

Economy


Advance Monthly Sales

Consumer Price Index CPI

Producer Price Index PPI

Retail Inventories

Personal Income

Gross Domestic Product GDP

Money Supply

Industrial Production

Productivity

Employment Situation

US International Trade

Factory Orders

Durable Goods

Construction Spending

Housing Starts

Vehicle Unit Sales

Stocks


Event Calendar

INBS's Profile

Stock Price

INBS's Financials

Business Description

Fundamentals

Charts & Quotes

INBS's News

Suppliers

INBS's Competitors

Customers & Markets

Economic Indicators

INBS's Growth

Company Segments

Screening


Stock Performance

Growth Rates

Profitability

Valuation

Dividend

Financial Strength

Efficiency

Largest Companies

Management Effectivness

Industries


At a Glance

Performance

Growth Rates

Profitability

Valuation

Financial Strength

Markets


At a Glance

Stocks

Cryptocurrencies

Sectors & Industries

Commodities

Currencies

News


At a Glance

Stocks

Economy

Industries

Other

Help


Sitemap

Advertise

About us

Glossary


Financial Terms

Technical Analysis

Fundamental Analysis

Energy Terms

Manufacturing Terms

Transportation Terms

Health Care

Insurance Terms

Economy Terms

Hotel & Leisure Terms

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2023 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
CSIMarket.com 1500 N. University Drive, Coral Springs, FL 33071